Medicare Advantage contract
H0504 Blue Shield of California
Local CCP · Parent: California Physicians' Service
⚠ Non-renewal
↓ Churn flag
Latest enrollment
66,655
2025-01
Year-over-year
-13.8%
contract book
National MA share
+0.1%
rank #122 of 936
Overall stars (latest)
★★★½ 3.5
summary rating
Enrollment trend · 5 years
Star rating history
| Year | Overall | Part C | Part D | Δ |
|---|---|---|---|---|
| 2020 | ★★★★ 4.0 | 4.0 | 4.5 | — |
| 2021 | ★★★★ 4.0 | 3.5 | 4.5 | — |
| 2022 | ★★★★ 4.0 | 4.0 | 4.5 | — |
| 2023 | ★★★★ 4.0 | 4.0 | 3.5 | — |
| 2024 | ★★★½ 3.5 | 3.0 | 4.0 | -0.5 |
Premium
Median monthly plan premium across this contract's plans, by year.
| Plan | Year | Monthly premium | Part D premium |
|---|---|---|---|
| H0504-015 | 2026 | $0.00 | $0.00 |
| H0504-017 | 2026 | $0.00 | $0.00 |
| H0504-021 | 2026 | $0.00 | $0.00 |
| H0504-026 | 2026 | $0.00 | $0.00 |
| H0504-028 | 2026 | $0.00 | $0.00 |
| H0504-038 | 2026 | $0.00 | $0.00 |
| H0504-039 | 2026 | $65.00 | $0.00 |
| H0504-040 | 2026 | $0.00 | $0.00 |
| H0504-041 | 2026 | $56.00 | $46.90 |
| H0504-043 | 2026 | $0.00 | $0.00 |
| H0504-047 | 2026 | $58.00 | $0.00 |
| H0504-050 | 2026 | $20.00 | $20.00 |
Premium analytics
Deeper cuts for investors and plan-strategy teams, delivered as a custom analysis.
Measure-level star movers
2023 → 2024- C23 Rating of Health Plan 5★ → 2★
- C20 Getting Appointments and Care Quickly 4★ → 1★
- C27 Health Plan Quality Improvement 5★ → 2★
- C19 Getting Needed Care 4★ → 2★
- C24 Care Coordination 4★ → 2★
- C18 Follow-up after Emergency Department Visit for People with Multiple High-Risk Chronic Conditions 2★ → 4★
🔒 Want a custom analysis on this? — which measures moved, cut-point sensitivity, and
projected next-year exposure.
Talk to us →
County enrollment
0 counties| State | County | Enrollment |
|---|
Want a custom analysis on this?
Talk to us →County market share vs. competitors
service-area overlapHead-to-head share by county against named competitors, with expansion whitespace and defended turf.
Want a custom analysis on this?
Talk to us →